This web site is intended for medical professionals working in an ICU or interested in Critical Care, but can also be accessed by the general public. The information provided here is made available for educational purposes only. The information given here is from textbooks/journals. I have provided the source, indicated references and given credit where applicable. Every post is linked to its source of information. Any kind of information posted on the web site is referenced and properly dated.

Friday, July 10, 2009

TRALI - Pathophysiology

The lung appears to be the main site for leukocyte activation and bears the majority of tissue damage in TRALI. Possible explanations for this include that the pulmonary microcirculation is the first to encounter transfusion-associated antibodies or immune complexes and that it also contains pulmonary macrophages that can become activated.

The pathogenesis of TRALI depends on the blood product transfused, the underlying mechanism, and “threshold effects” that (may) allow more than 1 mechanism to participate in the lung injury. Nearly all plasma-containing blood products and a variety of blood components have been implicated in TRALI pathogenesis, including whole blood, packed RBC, FFP, platelet concentrates or apheresis, granulocytes, cryoprecipitate, intravenous immunoglobulin, and bone marrow stem cells. Generally, TRALI reactions have not been attributed to washed red cells, albumin, and clotting factor concentrates.

The EHN (European Haemovigilance Network) subtypes TRALI based on underlying mechanism into immune (antibody mediated) or nonimmune TRALI (non-antibody mediated). Others, however, favor a “Two hit” model of TRALI pathogenesis that can apply to both antibody mediated and non-antibody mediated TRALI cases.

image

Ref: Journal of Intensive Care Medicine / Vol. 23, No. 2, March/April 2008

Click here to read 'TRALI – Definition'

Click here to read about 'Clinical Presentation and Diagnosis' of TRALI

No comments:

Post a Comment

ANSWERS/SUGGESTIONS